Abstract:The present article reviews the current evidence for antibody-drug conjugates (ADCs) in gynecologic cancer. ADCs consist of a highly selective monoclonal antibody for a tumor-associated antigen and a potent cytotoxic payload conjugated through a linker. Overall, the toxicity profiles of ADCs are manageable. Ocular toxicity is a known class effect of some ADCs and is managed with prophylactic corticosteroid and vasoconstrictor eye drops as well as dose interruptions/holds and dose modifications. In ovarian cancer, mirvetuximab soravtansine, an ADC targeting alpha-folate receptor (FRα), received US Food and Drug Administration (FDA) accelerated approval in November 2022 after data from the single-arm phase III SORAYA trial. A second ADC targeting FRα, STRO-002, received FDA fast track designation in August 2021. Multiple studies with upifitamab rilsodotin, an ADC comprising a NaPi2B-binding antibody, are underway. In cervical cancer, tisotumab vedotin, an ADC-targeting tissue factor, received FDA accelerated approval in September 2021 after the phase II innovaTV 204 trial. Tisotumab vedotin in combination with chemotherapy and other targeted agents is currently being evaluated. Although there are no currently approved ADCs for endometrial cancer, there are many under active evaluation, including mirvetuximab soravtansine. Trastuzumab-deruxtecan (T-DXd), an ADC targeting human epidermal growth factor receptor 2 (HER2), is currently approved for HER2-positive and HER2-low breast cancer and shows promise in endometrial cancer. Like all anticancer treatments, the decision for a patient to undergo therapy with an ADC is a personal choice that balances the potential benefits with the side effects and requires thorough and compassionate support of their physician and care team and shared decision making.

Research progress of antibody–drug conjugates in gynecologic cancer

Progress in the study of antibody-drug conjugates for the treatment of cervical cancer

A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer

Antibody-Drug Conjugates in Gynecologic Cancer

Antibody-drug conjugates in gynecologic malignancies

The target invites a foe: antibody-drug conjugates in gynecologic oncology

Advances in antibody-drug conjugates for gynecologic malignancies

Antibody-Drug Conjugates in Gynecologic Cancers

Bibliometric analysis of antibody-drug conjugates

Recent advances in antibody-drug conjugates for breast cancer treatment.

The research and development of antibody-drug conjugate for tumor immunotherapy

Antibody-drug Conjugates: Design and Clinical Progress

Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

Research progress on novel antibody drug conjugates in cancer therapy

[Antibody-Drug Conjugates in Breast Cancer and Gynecologic Cancer]

The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new era

Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions

Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer

Antibody-drug Conjugates and Their Application in the Treatment of Hematological Malignancies

Antibody-drug conjugates: the clinical development in gastric cancer